凱普生物(300639.SZ):擬以2220萬元對湖南友哲進行投資
格隆匯 1 月 12日丨凱普生物(300639.SZ)公佈,近日,公司與湖南友哲科技有限公司(“湖南友哲”)及其實際控制人梁光明簽署《投資合作框架協議》,公司擬以自有資金2220萬元對湖南友哲進行投資,投資完成後,公司持有湖南友哲20%的股權,並在產品、市場、科研、人才培養及學術交流方面展開深度合作。
湖南友哲由國防科技大學博士梁光明創辦,是一家將軍事目標識別技術、人工智能技術應用於醫學顯微鏡智慧檢驗的高科技企業,研製了行業領先的具有知識產權的GY66陰道微生態綜合分析儀等智能化檢測系統,實現女性生殖疾病檢驗的數字化、自動化、智能化、標準化,為用户提供先進儀器和相關試劑耗材,大大提高檢驗效率和準確性。
此次公司與湖南友哲及其實際控制人梁光明簽署《投資合作框架協議》,以自有資金對湖南友哲進行投資,旨在共同打造婦幼健康領域領先品牌,並在產品、市場、科研、人才培養及學術交流方面展開深度合作,有利於雙方在女性生殖道疾病檢測領域實現資源共享、優勢互補、互利共贏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.